Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56
Published March 22, 2017 · Recall initiated: February 7, 2017
Summary
FDA records drug Class II recall D-0517-2017, published March 22, 2017 and initiated February 7, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 7,628 HDPE bottles (228,840 tablets); Lot: Lot 30227056A; Exp. 03/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Nationwide
- Lot
- Lot 30227056A; Exp. 03/17
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDADoxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, RxFebruary 9, 2022
- FDAMimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDATretinoin Capsules, 10 mg, 100 count bottle, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454,February 9, 2022
- FDAPROTONIX I.V. (pantoprazole sodium) for Injection, Equivalent to 40 mg pantoprazole per vial, For I.V.March 22, 2017
- FDATriamcinolone 40 mg/mL 2 mL Single-Dose Vial for Injection, Preservative Free, Rx only, Compounded by IsomericMarch 22, 2017
Questions about this recall
Was Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56 recalled?
Yes. FDA published recall D-0517-2017 on March 22, 2017. Reported hazard: Failed Impurities/Degradation Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter